VIVUS, Inc.  

(Public, NASDAQ:VVUS)   Watch this stock  
Find more results for VVUS
1.10
0.00 (0.00%)
After Hours: 1.10 0.00 (0.00%)
Jun 24, 5:04PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.02 - 1.12
52 week 0.92 - 2.61
Open 1.05
Vol / Avg. 11.01M/543,313.00
Mkt cap 114.50M
P/E     -
Div/yield     -
EPS -0.87
Shares 104.09M
Beta 1.16
Inst. own 45%
Jul 28, 2016
Q2 2016 VIVUS Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 3, 2016
Q1 2016 VIVUS Inc Earnings Call
May 3, 2016
Q1 2016 VIVUS Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -82.93% -97.57%
Operating margin -29.57% -63.16%
EBITD margin - -28.11%
Return on average assets -18.99% -28.91%
Return on average equity - -246.86%
Employees 82 -
CDP Score - -

Address

351 E Evelyn Ave
MOUNTAIN VIEW, CA 94041-1530
United States - Map
+1-650-9345200 (Phone)
+1-650-9345389 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.

Officers and directors

David York Norton Chairman of the Board and Director
Age: 63
Bio & Compensation  - Reuters
Seth H. Z. Fischer Chief Executive Officer, Chief Commercial Officer, Director
Age: 59
Bio & Compensation  - Reuters
Mark K. Oki CPA Chief Financial Officer, Chief Accounting Officer
Age: 46
Bio & Compensation  - Reuters
John L. Slebir Esq. Senior Vice President - Business Development, General Counsel, Secretary
Age: 49
Bio & Compensation  - Reuters
Guy P. Marsh Vice President - U.S. Operations, General Manager
Age: 61
Bio & Compensation  - Reuters
Johann Noor Mohamed Vice President, Corporate Controller
Age: 43
Bio & Compensation  - Reuters
Wesley W. Day Ph.D. Vice President - Clinical Development
Age: 51
Bio & Compensation  - Reuters
Santosh T. Varghese M.D Vice President-Medical & Regulatory Affairs, Pharmacovigilance, and QA
Age: 44
Bio & Compensation  - Reuters
Herman Rosenman CPA Director
Age: 67
Bio & Compensation  - Reuters
Jorge Plutzky M.D. Independent Director
Age: 56
Bio & Compensation  - Reuters